Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Brad who wrote (504)	3/5/1998 12:54:00 PM
From: dexx	Respond to of 4650

When confirmation of Biomoda's upcoming public tests hits the New England Journal of Medicine and the American Medical Association, this stock (ADOT) will explode (because of their significant minority interest). Institutions like Columbia Health Care, etc. will be on top of this like you cannot believe. Dexx

To: Brad who wrote (504)	3/5/1998 1:48:00 PM
From: Jeffrey Beckman	Read Replies (1) \| Respond to of 4650

Brad/Andrew, Just to clarify, it seems that Biomoda's patents are related to the chemical binder, TCPP. According to Andrew's post, this is detected in vitro by fluorescent microscopy, and in the body by Positive Emmission Tomography or via detection of radioactive copper. The original press release states that ADOT will be given rights of refusal to manufacture the "scanners", but doesn't state that these are new inventions. Do you know if these scanners are a form of "Positive Emmission Tomography", fluorescent microscopy, or something completely different? I haven't seen any release mentioning specific scanners used in Biomoda's method, although I may have missed it. Thanks again, Jeff